64周减重16.6%！高剂量口服司美格鲁肽获FDA批准上市，诺和诺德大涨10%

Core Viewpoint - Novo Nordisk's oral semaglutide tablet Wegovy has been approved by the FDA for weight management and reducing cardiovascular event risks, marking a significant advancement in obesity treatment options [4][6]. Group 1: Approval and Market Impact - The approval of oral Wegovy signifies a new phase in weight loss drug competition, transitioning from injections to oral solutions that are effective, safe, and regulated [6]. - Following the announcement, Novo Nordisk's stock surged by 10% in after-hours trading, reflecting positive market sentiment [7]. Group 2: Clinical Evidence and Efficacy - The approval was based on data from the OASIS clinical trial and the SELECT cardiovascular outcomes study, with OASIS 4 being a pivotal trial [8]. - In the OASIS 4 trial, 307 participants lost an average of 16.6% of their body weight after 64 weeks on a daily 25 mg oral semaglutide regimen, comparable to the 2.4 mg weekly injection version [8]. - Approximately one-third of participants achieved a weight loss of 20% or more, addressing previous concerns about the efficacy of oral GLP-1 treatments [8]. Group 3: Safety and Long-term Management - OASIS 4 confirmed the known tolerability profile of semaglutide, with no new safety signals reported [11]. - The approval extends beyond weight loss, as it is also indicated for adults with known heart disease to reduce major cardiovascular event risks, redefining the role of weight loss drugs in chronic disease management [12]. Group 4: Future Development and Market Dynamics - The OASIS project encompasses around 1,300 participants across four studies, indicating that oral GLP-1 is now a core development path rather than a supplementary option [13]. - Novo Nordisk plans to launch oral Wegovy in the U.S. in January 2026, with applications submitted for approval in Europe and other regions [13]. - The dual availability of both injection and oral forms of Wegovy sets a new standard for market competition, shifting focus from efficacy to sustainable long-term management systems [13][14].